Heart Attack Linked With Higher Risk of Other Long-Term Health Conditions
Drug Topics
FEBRUARY 19, 2024
After myocardial infarction, all-cause mortality was the most frequent event, followed by heart failure, renal failure, and atrial fibrillation.
Mon.Feb 19, 2024
187 
California Passes First-in-Nation Law to Reduce Medication Errors, Address Pharmacy Staffing Concerns
Pharmacy Times
FEBRUARY 19, 2024
California's Stop Dangerous Pharmacies Act aims to improve patient safety by establishing new pharmacy staffing regulations and a medication error reporting system, arising from understaffed conditions.
Join 18,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
‘All of Us’ reports half of the genomes it has sequenced are from non-Europeans
STAT
FEBRUARY 19, 2024
Six years ago, the National Institutes of Health placed its biggest ever bet on precision medicine, launching a study to enroll over 1 million participants in an ambitious data-gathering gambit unmatched in its scope and diversity. Since then, Americans from all walks of life have been showing up and handing over their blood, spit, and pee to the project, dubbed “All of Us.
Full Scope of Pharmacy Practice: Reinventing the Future and Overcoming Barriers
Pharmacy Times
FEBRUARY 19, 2024
The full scope of pharmacy practice offers a transformative approach to health care delivery, promising improved patient outcomes, greater access to care, and efficient utilization of health care resources.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Niacin has long been a public health darling. But an excess could be bad for the heart, study suggests
STAT
FEBRUARY 19, 2024
Niacin, or vitamin B3, has long been a U.S. public health darling to the point that it is added, by law, to cereal products. But a new study published Monday in Nature Medicine points to a potentially concerning effect of an excess of the vitamin: It may increase the risk of cardiovascular disease. The study looked into two cohorts of patients without active heart disease, 60% of whom were treated with statins, and found a strong association between a metabolic product of excess niacin and an in
The Importance of Engaging Stakeholders When Implementing Bispecific Antibodies
Pharmacy Times
FEBRUARY 19, 2024
Matthew Pianko, MD, outlines the logistical considerations involved when implementing bispecific antibodies for the treatment of multiple myeloma, including the roles of the project champion and other stakeholders as part of a multidisciplinary team.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Roche’s Xolair is first medicine for food allergy in US
pharmaphorum
FEBRUARY 19, 2024
Fast approaching the end of its patent life, Roche and Novartis’ Xolair is going out with a bang, picking up a new approval as the first and only drug therapy for people with food allergies in the US.
FDA Approves Osimertinib With Chemotherapy for EGFRm NSCLC
Pharmacy Times
FEBRUARY 19, 2024
Osimertinib was previously approved as a monotherapy, the first-in-line global standard of care, for non–small cell lung cancer indications.
Transforming clinical data management systems for biotechnology trials
pharmaphorum
FEBRUARY 19, 2024
Learn how biotechnology trials are transforming clinical data management systems, leveraging machine learning and advanced protocols to enhance efficiency and accuracy in data collection and analysis.
Environmental Disinfection Can Be an Affordable, Effective Way to Reduce C Difficile Infections in Hospitals
Pharmacy Times
FEBRUARY 19, 2024
Targeted use of ultraviolet light and sporicidal treatment can reduce disease transmission alongside existing interventions.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Case Study: MGI and Alacris Theranostics
pharmaphorum
FEBRUARY 19, 2024
This case study explores the collaborative efforts of MGI and Alacris Theranostics in utilising molecular tumour profiling technology for advanced research. Discover the impact of this innovative approach on personalised medicine and treatment strategies.
8 vitamins for depression
The Checkup by Singlecare
FEBRUARY 19, 2024
Depression is one of the most common mental health conditions. In 2021 alone, 21 million adults —or 8.3% of American adults—experienced a major depressive disorder episode. It is more than just feeling sad; it’s a psychiatric disorder with symptoms that can be severe and can seriously affect your ability to function in daily life, socially, and at work.
Tagrisso-chemo cleared in US as 1st-line lung cancer therapy
pharmaphorum
FEBRUARY 19, 2024
AstraZeneca’s Tagrisso is cleared by FDA for use alongside chemotherapy as a frontline therapy for EGFR-positive lung cancer (NSCLC)
FDA Grants Accelerated Approval to Lifileucel, First-Ever Immunotherapy For Unresectable, Metastatic Melanoma
Drug Topics
FEBRUARY 19, 2024
The FDA's decision represents a landmark approval of a tumor-derived cellular therapy in a solid tumor cancer.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Study finds abortion pills by telehealth safe and effective
pharmaphorum
FEBRUARY 19, 2024
Ahead of landmark SCOTUS hearing, study finds telehealth access to abortion pill mifepristone is as safe and effective as in-clinic access
Rybelsus vs. Ozempic: Differences, similarities & side effects
The Checkup by Singlecare
FEBRUARY 19, 2024
When it comes to treatments for managing blood sugar levels, there are now more options than ever. Rybelsus and Ozempic are brand-name medications used to improve blood sugar in people with Type 2 diabetes. Although they’re not approved by the U.S. Food & Drug Administration (FDA) for weight management, many people find they lose weight with these medications, especially with lifestyle changes like a healthy diet and regular exercise.
At risk patients with rare diseases need a higher level of support - and the process must change
Outsourcing Pharma
FEBRUARY 19, 2024
February will see the 16th annual Rare Disease Day which raises awareness of the more than 7,000 identified rare diseases worldwide.
What causes nausea after eating? Related conditions and treatments
The Checkup by Singlecare
FEBRUARY 19, 2024
Chances are, you know the feeling. You ate a little too much of something a little too spicy, and now your stomach is upset, you feel a little sick as if you might vomit, and you’re looking for a bathroom. You’ve got nausea after eating, and you’re pretty sure you’re going to have diarrhea, too. It happens to just about everyone from time to time. But what, exactly, causes nausea after eating?
Initiative by Innovative Trials to boost patient retention inspired by boy's love of collecting
Outsourcing Pharma
FEBRUARY 19, 2024
The father of a boy diagnosed with acute lymphoblastic leukemia at the age of nine, inspired by his son's love of collecting, has created patches of positivity for children going through cancer treatment to collect.
10 foods that help with bloating and 8 foods to avoid
The Checkup by Singlecare
FEBRUARY 19, 2024
Belly bloat has many causes, including excess gas, fluid retention, constipation, menstruation, food intolerances, small intestinal bacterial overgrowth, and irritable bowel syndrome. But whatever the cause, you may be able to prevent bloating by tweaking your diet. We’ve consulted the experts to recommend 10 foods that help with bloating and eight foods to avoid for bloating.
Almirall licenses IL-21 antibody from Novo Nordisk
Pharmaceutical Technology
FEBRUARY 19, 2024
Almirall has signed a licensing agreement for the acquisition of worldwide rights to Novo Nordisk’s IL21-hindering antibody NN-8828.
AstraZeneca’s Tagrisso gets FDA approval, delaying lung disease progression by nine months
Outsourcing Pharma
FEBRUARY 19, 2024
Patients in the US with epidermal growth factor receptor mutated (EGFRm) advanced lung cancer can now receive an important new treatment option delaying disease progression by nearly nine additional months.
WHO initiative to enhance biomanufacturing in LMICs
European Pharmaceutical Review
FEBRUARY 19, 2024
The World Health Organization (WHO) has launched a new Biomanufacturing Workforce Training Initiative to help overcome challenges within the biomanufacturing sector in low- and middle-income countries’ (LMICs). The programme aims to support the limited capacity within the industry in LMICs. Another goal of the initiative is to manage the shortage of a qualified workforce in the production of biological products, such as vaccines, and monoclonal antibodies (mAbs).
Making “Rheum” for Biosimilars: Overcoming Reluctance
Pharmacy Times
FEBRUARY 19, 2024
Despite the proven efficacy of biosimilars, both patients and health care providers often have some reluctance when switching from an originator drug to a biosimilar.
Novel immunotherapy approved for melanoma
European Pharmaceutical Review
FEBRUARY 19, 2024
Amtagvi (lifileucel) is the first tumour-derived autologous T cell immunotherapy therapy to be approved by the US Food and Drug Administration (FDA) for certain adults with unresectable or metastatic melanoma” Amtagvi (lifileucel) is the first tumour-derived autologous T cell immunotherapy therapy to be approved by the US Food and Drug Administration (FDA) for certain adults with unresectable or metastatic melanoma.
Promoting Heart Health Awareness During American Heart Month
Pharmacy Times
FEBRUARY 19, 2024
Pharmacists can raise awareness about heart health during American Heart Month
Risk adjusted net present value: What is the current valuation of Dyne Therapeutics’s DYNE-251?
Pharmaceutical Technology
FEBRUARY 19, 2024
DYNE-251 is an antisense oligonucleotide commercialized by Dyne Therapeutics, with a leading Phase II program in Duchenne Muscular Dystrophy.
HP&M Welcomes Senior FDA Official, Ana Loloei, to the Firm
The FDA Law Blog
FEBRUARY 19, 2024
Hyman, Phelps & McNamara, P.C. (“HP&M”) is pleased to announce that Ana Loloei has joined the firm as Counsel. Ms. Loloei is a 14-year veteran of the FDA, where most recently she served as a Senior Regulatory Counsel in the Office of Policy at CDRH. While at FDA, Ms. Loloei also served as a Senior Policy Advisor in CDRH and as a Special Advisor in the Office of the Commissioner.
Iovance’s Amtagvi gains FDA accelerated approval for melanoma treatment
Pharmafile
FEBRUARY 19, 2024
Iovance Biotherapeutics has announced that the US Food and Drug Administration (FDA) has approved Amtagvi (lifileucel) suspension for intravenous infusion for the treatment of adult patients with unresectable or metastatic melanoma, previously treated with a PD-1 blocking antibody and, if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.
PDS-01ADC by PDS Biotechnology for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 19, 2024
PDS-01ADC is under clinical development by PDS Biotechnology and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma).
AstraZeneca’s Tagrisso approved by FDA for lung cancer treatment
Pharmafile
FEBRUARY 19, 2024
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Tagrisso for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The approval followed a Priority Review by the FDA and was based on results from the FLAURA2 phase 3 trial, […] The post AstraZeneca’s Tagrisso approved by FDA for lung cancer treatment appeared first on Pharmafile.
AZ, Daiichi eye December verdict for TROP2 ADC
pharmaphorum
FEBRUARY 19, 2024
FDA sets December date for decision on AstraZeneca and Daiichi Sankyo’s TROP2-directed ADC Dato-DXd as a therapy for lung cancer (NSCLC)
The History of Pharmaceutical Compounding
Compounding Pharmacy of America
FEBRUARY 19, 2024
The history and evolution of compounding medications goes back several decades, and over time, the practice has become more beneficial for patients. The post The History of Pharmaceutical Compounding appeared first on The Compounding Pharmacy of America.
Saxenda vs. Wegovy for weight loss
The Checkup by Singlecare
FEBRUARY 19, 2024
Weight management has become increasingly important in health care today, with many people seeking treatments for obesity or weight-related health issues. Two prescription medications that have become popular potential options for controlling weight are Saxenda and Wegovy. These brand-name injectable drugs are part of a drug class called glucagon-like peptide-1 (GLP-1) agonists.
Let's personalize your content